4:54 PM
 | 
May 16, 2018
 |  BC Extra  |  Clinical News

Merck, Pfizer report early data for PD-L1/ALK inhibitor combos

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) reported data from the Phase Ib/II JAVELIN Lung 101 trial evaluating the partners' PD-L1 inhibitor Bavencio avelumab in combination with Pfizer's anaplastic lymphoma kinase inhibitors to treat previously treated advanced non-small cell lung cancer (NSCLC). The data were released late Wednesday in an abstract ahead of the American Society of Clinical Oncology meeting in Chicago.

In the Phase Ib portion of the...

Read the full 329 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >